# Arcellx

Source: https://onco.cc/companies/arcellx/  
OnCo record `arcellx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Arcellx developed anito-cel, a CAR T-cell therapy for multiple myeloma that reprogrammes a patient's own immune cells to attack a marker called BCMA. Gilead bought the company in 2026 for about $7.8 billion ahead of a possible US approval.

## Summary

Arcellx developed anitocabtagene autoleucel (anito-cel), an autologous BCMA-directed CAR T-cell therapy built on the company's synthetic D-domain binder, for relapsed or refractory multiple myeloma. Anito-cel was co-developed and co-commercialised with Kite, a Gilead company, under a 2022 collaboration. The BLA for fourth-line relapsed or refractory multiple myeloma, supported by the phase 1 study (NCT04155749) and the pivotal phase 2 iMMagine-1 study (NCT05396885), was accepted by the FDA with a PDUFA date of 23 December 2026. Arcellx listed on Nasdaq in February 2022 (gross proceeds about $142 million). In February 2026 Gilead agreed to acquire the company for $115 per share in cash plus a $5 contingent value right, an implied equity value of about $7.8 billion, and completed the tender offer and merger on 28 April 2026. Arcellx is now a wholly owned subsidiary of Gilead and arcellx.com redirects to Kite.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Redwood City, CA
- Type: cell-therapy
- Website: https://www.kitepharma.com/

## Notes

- Former Nasdaq ticker ACLX, delisted after the April 2026 merger. The 2022 IPO release was datelined Gaithersburg, Maryland; the 2026 acquisition release is datelined Redwood City.

## Sources

- Official website: https://www.kitepharma.com/
- Gilead to acquire Arcellx (February 2026): https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel
- Gilead completes acquisition (April 2026): https://www.kitepharma.com/news/press-releases/2026/4/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel
- IPO closing release (8-K, February 2022): https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)
- trials: [iMMagine-1](https://onco.cc/trials/immagine-1/)

---
JSON: https://onco.cc/api/v1/entities/arcellx.json